



CooperVision®

I WEAR MISIGHT® 1 DAY
SO I CAN BE THE
NEXT CHAMPION ^

^ Not a real patient or testimonial



Recommend **MiSight® 1 day**
contact lenses for
myopia management

See the Science, Safety and Success of MiSight® 1 day contact lenses

SCIENCE



The first soft contact lens approved by the U.S. FDA to slow the progression of myopia in children aged 8-12 years at the initiation of treatment^{1,1*}

7 YEARS

The only soft contact lens proven by 7 years of clinical data to significantly slow myopic progression with no rebound effect^{1,4,*†}

Proven efficacy



Cuts myopia progression by approx. **50%**^{9*}



90% of myopic eyes respond^{2,*}



Children with faster-progressing myopia receive the **maximum benefit**^{2,†}

Sustained benefits



Works at **any age** a child starts treatment (ages 8+ years)^{9††}

No rebound effect



Myopia control benefits are **retained** in children who ended their treatment^{3,4†}

MiSight® 1 day is the **only soft contact lens** studied post-treatment^{3,4††}



Atropine and orthokeratology studies have shown **post-treatment rebound effect**^{3,4††}

^{*}Compared to a single-vision, 1-day lens over a three-year period, rate of progression maintained out to 6 years. [†]US FDA indications for Use: MiSight® 1 day (omafilcon A) Soft (Hydrophilic) Contact Lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 dioptres (spherical equivalent) with ≤ 0.75 dioptres of astigmatism. The lens is to be discarded after each removal. ^{††}On average, there was no indication that accumulated treatment effect gained following 3 or 6 years of MiSight® 1 day wear was lost during a 12-month cessation study in children aged 8-15 at initiation of treatment. Instead, eye growth reverted to expected, age average myopic progression rates. [‡]Using measured and modeled data, pooled across ages (8-17 years), MiSight® 1 day slowed myopia progression by an average of approximately 50%. [§]90% of myopic eyes respond to MiSight® 1 day treatment; ages 11-15 years at start of wear, n=90. [¶]In children with myopia aged 11-15 at the start of wear (n=90). ^{||}Children with myopia fit with MiSight® 1 day contact lenses (ages 8-15 years) continued to experience slowed myopia progression as long as they remained in treatment. ^{‡‡}There is currently no post-treatment evidence for spectacles or other soft contact lenses.

SAFETY



Zero serious adverse events related to contact lens wear observed across 469 patient-wearing years in a clinical study^{5,6}



Safety observations
Over 6 years, **99%** of all slit lamp observations were **≤ grade 1**^{3,††}



Minimal handling
MiSight® 1 day is a **single-use** contact lens, with no need for cleaning or storing⁵



MiSight® 1 day contact lenses have demonstrated an **excellent safety profile**⁵

SUCCESS



Children prefer MiSight® 1 day contact lenses to glasses^{7,8§}



Adherence with recommended wearing time
Children wore them for at least **10 hours/day**^{2§§}



Child-friendly and easy-to-use
85% of children, with no contact lens-wearing experience, found MiSight® 1 day lenses **easy** to apply after 1 month of wear⁷



Appropriate
Even 8-year-olds can **confidently** apply and remove them on their own⁷



Comfortable
95% of parents rated their children **'happy'** with the comfort of MiSight® 1 day lenses^{10§§§}

[†]Biomechanics used 0-4 grading scale. [§]95%—100% of children expressed a preference for contact lenses over glasses at each visit over 36 months. ^{§§}How much do you like wearing your contact lenses? ^{§§§}87/97 (90%) Top box I like contact lenses the best. Subjective response at 60 months. ^{§§§§}Mean wearing times at 72-month visit was 13.92 hours/day (children refit to MiSight® 1 day) and 13.90 hours/day (children wearing MiSight® 1 day for the 6-year study duration). Children aged 8-12 years at the initiation of treatment. ^{††}During a 3-year study of their children (aged 8-15 years) wearing MiSight® 1 day lenses.

Recommend MiSight® 1 day contact lenses for myopia management:



SCIENCE

- The first soft contact lens approved by the U.S. FDA to slow the progression of myopia in children aged 8–12 years at the initiation of treatment^{1*†}
- The only soft contact lens proven by 7 years of clinical data to significantly slow myopic progression with no rebound effect^{1-4*†}



SAFETY

Zero serious adverse events related to contact lens wear observed across 469 patient-wearing years in a clinical study^{5,6}



SUCCESS

Preferred by 9/10 children to glasses^{7,8\$#}



For more information, contact your CooperVision Business Development Manager or visit www.coopervision.net.au

*Plastic neutrality is established by purchasing credits from Plastic Bank. A credit represents the collection and conversion of one kilogram of plastic that may reach or be destined for waterways. CooperVision purchases credits equal to the weight of plastic in our contact lens orders in a specified time period. Contact lens plastic is determined by the weight of plastic in the blister, the lens and the secondary (outer carton) package, including laminates, adhesives, and auxiliary inputs (e.g. ink). References: 1. Chamberlain P *et al. Optom Vis Sci* 2019;96:556–567. 2. Chamberlain P *et al. Optom Vis Sci*. 2022;99(3):204–12. 3. Chamberlain P *et al. Optom Vis Sci* 2021;98:E-abstract 210049. 4. Hammond D *et al. Optom Vis Sci* 2021;98:E-abstract 215130. 5. Woods J *et al. Cont Lens Anterior Eye* 2021;44(4):101391. 6. CooperVision data on file, 2022. 7. Sulley A *et al. Optom Vis Sci* 2019;96(E-abstract):195252. 8. CooperVision® data on file, 2023. 9. Arumugam B *et al. Invest Ophthalmol Vis Sci*. 2021;62(8):2333. 10. CooperVision data on file, 2018. 3-year data for RCT with MiSight® 1 day and Proclear® 1 day. For instructions for use refer to <https://coopervision.net.au/patient-instruction>. MiSight® and CooperVision® are registered trademarks of the Cooper Companies, Inc. and its subsidiaries. SA10744 EMVC000973 ©2024 CooperVision.